Study guide

Endometrial and ovarian cancer

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Endometrial and ovarian cancer

Key Takeaways Explain This Topic AI

Endometrial sampling investigates concerning postmenopausal bleeding.

A raised CA125 is not specific for ovarian malignancy.

High-risk adnexal masses require gynaecological-oncology assessment.

Last updated: October 2026

Endometrial Carcinoma

Endometrial cancer is the most common gynaecological malignancy in Australia, with over 3,300 new diagnoses annually. It predominantly affects postmenopausal women, with a median age at diagnosis of 63 years.

Histological Subtypes & Pathogenesis

Type I (Endometrioid Adenocarcinoma, ~80%) : Oestrogen-dependent, arising against a background of atypical endometrial hyperplasia. Characterized by PTEN mutations, microsatellite instability, and PIK3CA mutations. Typically low-grade, confined to the uterus, and carries a favourable overall prognosis.

Type II (Non-Endometrioid: Serous and Clear Cell, ~20%) : Oestrogen-independent, arising in an atrophic endometrium in older postmenopausal women. Characterized by TP53 mutations and HER2 amplification. Highly aggressive, poorly differentiated, prone to early intraperitoneal and lymphovascular dissemination, with poor 5-year survival.

Risk Factors for Endometrial Cancer

All risk factors for Type I disease reflect prolonged, unopposed oestrogenic stimulation of the endometrium without luteal progesterone:

Obesity ( B M I ≥ 30 kg/m 2 BMI \ge 30\text{ kg/m}^2 BM I ≥ 30 kg/m 2 ) : The single greatest modifiable risk factor. Adipocytes contain aromatase enzymes that convert adrenal androstenedione into estrone.

Endogenous Oestrogen Exposure : Early menarche ( < 12 years < 12\text{ years} < 12 years ), late menopause ( > 55 years > 55\text{ years} > 55 years ), nulliparity, and chronic anovulation (polycystic ovary syndrome).

Exogenous Oestrogens : Oestrogen-only menopausal hormone therapy in a woman with an intact uterus, or tamoxifen therapy (which acts as a partial oestrogen agonist on endometrial tissue while antagonizing breast tissue).

Genetic Syndromes : Lynch syndrome (hereditary non-polyposis colorectal cancer / HNPCC, caused by germline mutations in DNA mismatch repair genes: MLH1, MSH2, MSH6, PMS2) conveys a 40% to 60% lifetime risk of endometrial carcinoma. Universal screening for Lynch syndrome via reflex mismatch repair immunohistochemistry (MMR IHC) is performed on all endometrial cancers diagnosed in Australia.

Clinical Presentation and Postmenopausal Bleeding (PMB) Workup

Cardinal Symptom : Any vaginal bleeding occurring ≥ 12 months \ge 12\text{ months} ≥ 12 months following the menopause is postmenopausal bleeding (PMB). Endometrial cancer is the underlying cause in approximately 10% of women presenting with PMB (the remaining 90% have benign causes: atrophic vaginitis, endometrial atrophy, or endometrial polyps). In any postmenopausal woman, endometrial cancer is the primary diagnosis to exclude.

First-Line Diagnostic Investigation: Transvaginal Ultrasound (TVUS) :

In postmenopausal women with PMB, an endometrial thickness ≤ 4 mm \le 4\text{ mm} ≤ 4 mm with a thin, homogeneous, distinct stripe carries a > 99 % > 99\% > 99% negative predictive value for endometrial cancer. If bleeding does not recur, conservative observation is appropriate.

An endometrial thickness > 4 mm > 4\text{ mm} > 4 mm , an irregular or heterogeneous stripe, or persistent/recurrent bleeding mandates urgent histological tissue sampling .

Histological Sampling Modalities :

Outpatient Pipelle endometrial aspiration biopsy : High diagnostic accuracy for global endometrioid cancer, but may miss focal polyps or fundal lesions.

Hysteroscopy with Dilatation and Curettage (D&C) : Indicated if Pipelle biopsy is inadequate, cannot traverse the internal os due to cervical stenosis, demonstrates hyperplasia, or if abnormal bleeding recurs despite a benign Pipelle result.

Surgical Management and Adjuvant Therapy

Definitive treatment consists of total laparoscopic hysterectomy with bilateral salpingo-oophorectomy (TLH/BSO) with sentinel lymph node mapping or selective pelvic and para-aortic lymphadenectomy.

Adjuvant treatment (vaginal vault brachytherapy, pelvic external beam radiotherapy, or carboplatin/paclitaxel systemic chemotherapy) is tailored to FIGO stage and molecular risk groups (POLE ultramutated, MMR-deficient, p53 abnormal, or no specific molecular profile).

Ovarian Carcinoma

Ovarian cancer has the highest mortality of all gynaecological malignancies in Australia due to its insidious onset, absence of effective population screening, and presentation at an advanced stage (Stage III or IV in > 70 % > 70\% > 70% of cases).

Histopathology

Epithelial Ovarian Carcinoma (EOC, > 90%) : The predominant histological subtype is high-grade serous ovarian carcinoma (HGSOC, 70%) . Contemporary pathogenetic evidence proves that most HGSOCs arise from the fimbriated end of the fallopian tubes as serous tubal intraepithelial carcinomas (STICs), subsequently shedding onto the ovarian surface and peritoneum.

Other epithelial subtypes include endometrioid and clear cell carcinomas (frequently arising from pre-existing pelvic endometriosis), and mucinous carcinomas.

Non-epithelial tumours include germ cell tumours (dysgerminomas, yolk sac tumours; typically in young women aged 15–30, secreting β \beta β -hCG, AFP, or LDH) and sex cord-stromal tumours (granulosa cell tumours secreting oestrogen and inhibin, producing abnormal bleeding).

Clinical Presentation: The "Silent" Symptoms

Symptoms are typically subacute and non-specific, frequently misattributed to irritable bowel syndrome or menopause. Hallmark symptoms occurring on > 12 days per month > 12\text{ days per month} > 12 days per month for < 12 months < 12\text{ months} < 12 months include:

Persistent abdominal bloating or increased abdominal girth (ascites).

Early satiety and difficulty completing normal meals.

Persistent pelvic or lower abdominal pain.

Increased urinary urgency or frequency.

Unexplained fatigue, weight loss, or change in bowel habits.

Diagnostic Workup & Risk of Malignancy Index (RMI)

Physical Examination : Bimanual pelvic examination may detect an irregular, firm, fixed adnexal mass; abdominal examination may reveal ascites (fluid wave) or an omental "cake".

Biomarkers : Serum Cancer Antigen 125 (CA-125) is elevated in > 80 % > 80\% > 80% of advanced epithelial ovarian cancers. However, CA-125 is non-specific in premenopausal women, as it can be elevated by benign conditions (endometriosis, adenomyosis, fibroids, pelvic inflammatory disease, pregnancy, and menstruation). In postmenopausal women, elevated CA-125 is highly predictive of malignancy.

Pelvic Transvaginal and Transabdominal Ultrasound : Evaluates mass size, architecture (unilocular vs multilocular), solid vascular components, thick septations, papillary projections, bilateral involvement, and the presence of ascites.

Risk of Malignancy Index (RMI) : Combines menopausal status ( M M M ), ultrasound score ( U U U ), and absolute serum CA-125 level ( U / mL U/\text{mL} U / mL ): R M I = U × M × CA-125 RMI = U \times M \times \text{CA-125} RM I = U × M × CA-125

Ultrasound Score ( U U U ) : 1 point each for multilocular cysts, solid areas, bilateral lesions, ascites, and intra-abdominal metastases ( U = 0 U = 0 U = 0 for 0 features; U = 1 U = 1 U = 1 for 1 feature; U = 3 U = 3 U = 3 for 2 to 5 features).

Menopausal Status ( M M M ) : Premenopausal = 1; Postmenopausal = 3.

Clinical Threshold : An R M I > 200 RMI > 200 RM I > 200 has a sensitivity of ~88% and specificity of ~97% for ovarian malignancy. Any patient with an R M I > 200 RMI > 200 RM I > 200 must be referred immediately to a certified gynaecological oncologist within a specialized tertiary cancer centre.

Ovarian tissue assessment: Do not routinely aspirate an intact suspicious ovarian cyst. In advanced disease, a suitable peritoneal/omental biopsy may be appropriate before neoadjuvant treatment. The oncology MDT determines the strategy from extent, fitness and diagnostic need.

Genetic Susceptibility & Risk-Reducing Surgery

Up to 15% to 20% of epithelial ovarian cancers are attributable to inherited germline mutations:

BRCA1 : Lifetime ovarian cancer risk of 40% to 50% .

BRCA2 : Lifetime ovarian cancer risk of 15% to 25% .

Lynch Syndrome : Lifetime ovarian cancer risk of 10% to 12% .

All women diagnosed with non-mucinous epithelial ovarian cancer in Australia are offered germline and somatic genetic testing.

Prophylactic Bilateral Salpingo-Oophorectomy (RRBSO) : The standard risk-reducing intervention for mutation carriers, recommended at age 35 to 40 years for BRCA1 , and age 40 to 45 years for BRCA2 (after completion of childbearing). Routine population screening with CA-125 and TVUS has not demonstrated mortality reduction and is strictly not recommended for average-risk asymptomatic women.

Clinical comparison: NCSP Triage Pathways, Endometrial Cancer Workup, and Ovarian Cancer Risk Stratification

NCSP: HPV 16 / 18 : Primary Screening or Triage Tool: Primary HPV nucleic acid test; Diagnostic Threshold / Action Trigger: Oncogenic HPV 16 and/or 18 detected; Mandatory Clinical Action: Mandatory direct referral for colposcopy regardless of reflex cytology

Negative follow-up HPV: In the standard intermediate-risk follow-up pathway, an HPV-negative 12-month test returns to routine five-year screening. Do not require an extra 12-month test without a separate indication.

NCSP: High-Grade Cytology : Primary Screening or Triage Tool: Reflex Liquid-Based Cytology (LBC); Diagnostic Threshold / Action Trigger: LBC HSIL, ASC-H, atypical glandular cells; Mandatory Clinical Action: Immediate referral for colposcopy

Postmenopausal Bleeding : Primary Screening or Triage Tool: Transvaginal ultrasound (TVUS); Diagnostic Threshold / Action Trigger: Endometrial thickness ≤ 4 mm \le 4\text{ mm} ≤ 4 mm (thin/homogeneous); Mandatory Clinical Action: Reassure; observe clinically if bleeding ceases; repeat if bleeding recurs

Postmenopausal Bleeding : Primary Screening or Triage Tool: Transvaginal ultrasound (TVUS); Diagnostic Threshold / Action Trigger: Endometrial thickness > 4 mm > 4\text{ mm} > 4 mm or heterogeneous; Mandatory Clinical Action: Mandatory Pipelle endometrial biopsy or hysteroscopy with D&C

Adnexal Mass Evaluation : Primary Screening or Triage Tool: Risk of Malignancy Index (RMI); Diagnostic Threshold / Action Trigger: R M I = U × M × CA-125 > 200 RMI = U \times M \times \text{CA-125} > 200 RM I = U × M × CA-125 > 200 ; Mandatory Clinical Action: Urgent referral to certified gynaecological oncologist in tertiary centre

BRCA1 Mutation Carrier : Primary Screening or Triage Tool: Genetic counselling & testing; Diagnostic Threshold / Action Trigger: Completion of childbearing (age 35–40); Mandatory Clinical Action: Risk-reducing bilateral salpingo-oophorectomy (RRBSO)

Primary references (checked 7 October 2026): National cervical screening provider resources .